Certain Options of AtriCure, Inc. are subject to a Lock-Up Agreement Ending on 2-JAN-2019.
January 02, 2019
Share
Certain Options of AtriCure, Inc. are subject to a Lock-Up Agreement Ending on 2-JAN-2019. These Options will be under lockup for 90 days starting from 4-OCT-2018 to 2-JAN-2019.
Details:
The company, its executive officers, directors, selling stockholders, and holders of substantially all of its outstanding shares of capital stock and other securities have agreed that, for a period of 180 days from the date of the prospectus, they will not, without the prior written consent of underwriter, dispose of or hedge any shares or any securities convertible into or exchangeable for common stock. Citigroup Global Markets Inc. and Jefferies LLC in their sole discretion may release any of the securities subject to these lock-up agreements at any time, which, in the case of officers and directors, shall be with notice.
AtriCure, Inc. provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The Company's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.
ATRICURE, INC. 
